

To,

Date: 13.11.2020

BSE Limited
P.J. Towers, Dalal Street,
Mumbai – 400 001

Metropolitan Stock Exchange of India Limited
Vibgyor Towers, 4th floor, Plot No. C62, Opp. Trident
Hotel, BandraKurla Complex, Bandra (E),
Mumbai- 400 098

Dear Sir/Madam,

Sub: Outcome of board meeting under Regulation 30 read with 33 (3) (c) of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015

Ref: (Scrip code: 539267/ DRHABEEB)

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Dr Habeebullah Life Sciences Limited held on Friday, 13.11.2020 at 3.30 P.M. at the registered office of the Company, the following were considered and approved by the Board:


1. Un-Audited financial results (Standalone & Consolidated) for the quarter II and half year ended 30.09.2020.
2. Limited Review Report (standalone & consolidated) along with Declaration as per Regulation 33 of SEBI (LO&DR) Regulations, 2015 for the quarter ended 30.09.2020


The meeting of the Board of Directors commenced at 03:30 P.M.(IST) and concluded at 5.30 P.M (IST).

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,
For Dr Habeebullah Life Sciences Limited


K. Krishnam Raju
Whole-Time Director
(DIN: 00874650)



Encl: as above

Dr Habeebullah Life Sciences Ltd

(Formerly Known as PC Products India Limited)

Regd. Off : 2-5-36/CLRD/1, Chintalmet X Roads, Upperpally, Rajendra Nagar Mandal, Hyderabad-500040, TS, India.
Corp Off : No. 11, Phase 1, Vasudeva's Bloomfield Elation, Khajaguda, Nanakramguda, Hyderabad-500008, TS, India.
CIN No.: L85110TG1996PLC099198. Email: cs@drhisl.com, info@drhisl.com, pcproductindia@gmail.com
Contact No.: 040 - 2970 3333, +91 9036057370. Website : www.drhisl.com

PART-I		STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2020					(Amount in Lakhs.)
S.No	Particulars	Quarter ended			Half Year ended		Year ended 31-03-2020
		3 Months ended 30-09-2020	Corresponding 3 months ended in previous year 30-09-2019	Preceding 3 months ended 30-06-2020	Half year ended 30-09-2020	Half year ended 30-09-2019	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	
I	Revenue from Operations	-	35.26	1.30	1.30	77.48	143.19
II	Other Income	3.64	5.64	3.54	7.18	5.64	15.82
III	Total Revenue (I+II)	3.64	40.90	4.84	8.48	83.12	159.01
IV	Expenses						
	Cost of Material Consumed	-	5.90	0.19	0.19	13.15	22.49
	Employee benefits expense	12.72	29.02	12.24	24.96	58.90	125.96
	Depreciation and Amortisation expense	0.27	0.24	0.26	0.53	0.48	1.08
	Other Expenses	21.13	55.15	18.48	39.61	120.27	198.49
	Total Expenses	34.12	90.31	31.17	65.29	192.80	348.02
V	Profit/(Loss) from before Exceptional Items and tax (I-IV)	(30.48)	(49.41)	(26.33)	(56.81)	(109.68)	(189.01)
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit/(Loss) before tax (V-VI)	(30.48)	(49.41)	(26.33)	(56.81)	(109.68)	(189.01)
VIII	Tax Expense:						
	Current Tax	-	-	-	-	-	-
	Deferred Tax	-	-	-	-	-	-
IX	Profit/ (Loss) for the period from Continuing operations (VII-VIII)	(30.48)	(49.41)	(26.33)	(56.81)	(109.68)	(189.01)
X	Profit/ (Loss) from discontinuing operations	-	-	-	-	-	-
XI	Tax Expense of discontinuing operations	-	-	-	-	-	-
XII	Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)	-	-	-	-	-	-
XIII	Profit/ (Loss) for the period (IX+XII)	(30.48)	(49.41)	(26.33)	(56.81)	(109.68)	(189.01)
XIV	Other Comprehensive Income						
	A) (i) Items that will not be reclassified to profit or loss						
	(ii) Income Tax related to items that will not be reclassified to profit or loss						
	B) (i) Items that will be reclassified to profit or loss						
	(ii) Income Tax relating to items that will be reclassified to profit or loss	1.42	-	-	1.42	-	1.85
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)	(29.06)	(49.41)	(26.33)	(55.39)	(109.68)	(187.16)
XVI	Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each)						
	1) Basic	(0.20)	(0.33)	(0.18)	(0.37)	(0.74)	(1.28)
	2) Diluted	(0.20)	(0.33)	(0.18)	(0.37)	(0.74)	(1.28)
XVII	Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each)						
	1) Basic	-	-	-	-	-	-
	2) Diluted	-	-	-	-	-	-
XVIII	Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/- each)						
	1) Basic	(0.20)	(0.33)	(0.18)	(0.37)	(0.74)	(1.28)
	2) Diluted	(0.20)	(0.33)	(0.18)	(0.37)	(0.74)	(1.28)
XIX	Paid Up Equity Share Capital (Face Value of INR 10/- per share)	1,480.87	1480.87	1,480.87	1,480.87	1480.87	1480.87

Notes:

- The above unaudited standalone financial results for the quarter and half year ended 30 September 2020 have been subject to a limited review by the statutory auditors, and reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on Friday 13 November 2020.
- The unaudited standalone financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under section 133 of Companies Act, 2013 and other accounting principles generally accepted in India and in terms Regulation 33 of SEBI (LODR) Regulations, 2015.
- The format for the Standalone Unaudited quarterly and half year results as prescribed in SEBI Circular CRI/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply with the requirements of SEBI Circular CRI/CFD/FAC/62/2016 dated July 5, 2016 and exemption as given under clause 2.6.2(i) has been availed.
- The EPS for quarters has not been annualized.
- The company continues to consider the impact of COVID-19 pandemic in assessing the improvement of business and recoverability of receivables. For this purpose, the company considered internal and external sources of information up to the date of approval of these financial results. The Company based on its judgements, estimates and assumptions expects to recover the carrying amount of receivables and other assets. The impact of the global health pandemic may be different from that estimated as at the date of approval of financials results and the Company will continue to closely monitor any material changes to future economic conditions. Entity operated its hospital in the month of June'2020 only for seven days after relaxation of lockdown rules but later the same was shut down and not started till date. Hence there is no revenue in second quarter i.e. July 2020 - September 2020.
- The Company has only one reportable segment i.e., Health Care Sector. Hence, the separate disclosure on Segment information is not required.
- The unaudited financial results for the quarter and half year ended 30 September, 2020 are also available on the website of the Company www.drhlsl.com.
- The Previous quarters/ year's figures have been regrouped/rearranged wherever necessary, for the purpose of comparison.

Place : Hyderabad
Date : 13/11/2020

For DR HABEEBULLAH LIFE SCIENCES LIMITED

K. Krishnam Raju
Executive Chairman (DIN 00874650)



DR Habeebullah Life Sciences Limited
Standalone Statement of Assets and Liabilities

(Amount in Lakhs.)

Particulars	Half Year Ended 9/30/2020 (Unaudited)	Year Ended 3/31/2020 (Audited)
ASSETS		
1 Non Current Assets		
a Property, Plant and Equipment	2.22	2.74
b Capital Work In Progress	-	-
c Investment Property	-	-
d Goodwill	-	-
e Other Intangible Assets	-	-
f Intangible Assets under development	321.45	303.23
g Biological assets other than bearer plants	-	-
h Financial Assets:	-	-
i Investments	487.06	487.06
ii Trade Receivables	-	-
iii Loans	-	-
iv Others	204.28	204.28
v Loans	-	-
vi Others	-	-
i Deferred Tax Assets (net)	-	-
j Other Non Current Assets	-	-
Total Non Current Assets	1,015.01	997.30
2 Current Assets		
a Inventories	12.92	13.11
b Financial Assets	-	-
i Investments	-	-
ii Trade Receivables	214.26	217.51
iii Cash and Cash Equivalents	0.80	2.35
iv Bank balances other than above	-	-
v Loans and Advances	134.00	134.00
vi Other financial assets	30.75	24.10
c Current Tax Assets (net)	-	-
d Other Current Assets	304.55	304.31
Total Current Assets	697.28	695.40
Total Assets	1,712.29	1,692.70
EQUITY AND LIABILITIES		
1 Equity		
a Equity Share Capital	1,480.87	1,480.87
b Other Equity	-	-
i Share Warrants	-	-
ii Reserves and Surplus	(293.33)	(237.94)
iii Non-Controlling Interests	-	-
Total - Equity	1,187.54	1,242.93
2 Liabilities		
Non Current Liabilities		
a Financial Liabilities	-	-
i Borrowings	-	-
ii Trade Payables	-	-
iii Other Financial Liabilities	-	-
b Provisions	14.48	14.50
c Deferred Tax Liabilities (net)	-	-
d Other Non Current Liabilities	-	-
Total Non Current Liabilities	14.48	14.50
Current Liabilities		
a Financial Liabilities	-	-
i Borrowings	211.30	179.15
ii Trade Payables	34.93	30.50
iii Other Financial Liabilities	-	-
b Other Current Liabilities	261.20	223.20
c Provisions	2.84	2.43
d Current Tax Liabilities (net)	-	-
Total Current Liabilities	510.27	435.28
Total - Equity and Liabilities	1,712.29	1,692.70

For DR HABEEBULLAH LIFE SCIENCES LIMITED

Place: Hyderabad
Date: 13/11/2020

K. Krishnam Raju
Executive Chairman
(DIN 00874650)



DR HABEEBULLAH LIFE SCIENCES LIMITED
STANDALONE STATEMENT OF CASH FLOWS

(Amount in Lakhs.)

PARTICULARS	Half Year ended September 30, 2020	Half Year ended September 30, 2019
A. CASH FLOW FROM OPERATING ACTIVITIES :		
Net profit before tax	(55.39)	(109.68)
<u>Adjustment for:</u>		
Depreciation and Amortisation	0.53	0.48
Interest Expenses	-	-
Interest Earned	-	(5.64)
Cash Flows from Operations before changes in assets and liabilities	(54.86)	(114.84)
<u>Movements in Working Capital::</u>		
(Increase)/ Decrease in trade receivables	3.26	0.53
(Increase)/ Decrease in Short Term Loans and Advances	-	-
(Increase)/ Decrease in other Current Assets	(0.24)	(74.73)
(Increase)/ Decrease in other other financial Assets	(6.65)	-
(Increase)/ Decrease in Inventories	0.19	0.11
Increase / (Decrease) in Trade Payables	4.43	9.88
Increase/ (Decrease) in Other current liabilities	38.00	71.91
Increase/ (Decrease) in Current Provisions	0.40	(0.77)
Change in Working Capital	39.40	6.93
<u>Changes in non current assets and liabilities</u>		
Decrease/(Increase) in loans & advances	-	(1.73)
(Decrease)/Increase in Long Term Borrowings	-	-
(Decrease)/Increase in Long Term Provisions	(0.01)	0.76
Changes in non current assets and liabilities	(0.01)	(0.97)
<u>Cash Generated From Operations</u>	<u>(15.47)</u>	<u>(108.88)</u>
Less: Taxes paid	-	-
Net Cash from operating activities(A)	(15.47)	(108.88)
B. CASH FLOW FROM INVESTING ACTIVITIES		
(Increase) / Decrease in Fixed assets and Capital Work In progress	(18.23)	(48.66)
Bank Balances not considered as Cash and Cash equivalents	-	-
Investment in equity Shares	-	-
Interest received	-	5.64
Net cash used in Investing activities (B)	(18.23)	(43.02)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Increase / (Decrease) in Share Capital	-	150.00
Increase / (Decrease) in Borrowings	32.15	2.75
Interest paid	-	-
Net cash Flow from Financing Activities (C)	32.15	152.75
Net Increase/(Decrease) in cash & cash equivalents [A+B+C]	(1.55)	0.85
Cash & Cash Equivalents At The Beginning Of The Year	2.35	1.50
Cash & Cash Equivalents At The End Of The Year	0.80	2.35

For and on behalf of the Board
for DR HABEEBULLAH LIFE SCIENCES LIMITED



(K. Krishnam Raju)
Whole-time Director & Chairman
DIN: 00874650



Place: Hyderabad
Date: 13/11/2020

PART-I CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2020							(Amount in Lakhs.)
S.No	Particulars	Quarter ended			Half Year ended		Year ended
		3 Months ended 30-09-2020	Corresponding 3 months ended in previous year 30-09-2019	Preceding 3 months ended 30-06-2020	Half year ended 30-09-2020	Half year ended 30-09-2019	31-03-2020
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations	-	35.26	1.30	1.30	77.48	143.19
II	Other Income	3.64	5.64	3.54	7.18	5.64	15.82
III	Total Revenue (I+II)	3.64	40.90	4.84	8.48	83.12	159.01
IV	Expenses						
	Cost of Material Consumed	-	5.90	0.19	0.19	13.15	22.49
	Employee benefits expense	13.32	33.37	12.84	26.16	64.20	139.96
	Depreciation and Amortisation expense	0.33	0.39	0.33	0.66	0.63	1.63
	Other Expenses	21.29	55.23	18.63	39.92	128.16	200.20
	Total Expenses	34.94	94.89	31.99	66.93	206.14	364.28
V	Profit/(Loss) from before Exceptional Items and tax (I-IV)	(31.30)	(53.99)	(27.15)	(58.45)	(123.02)	(205.27)
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit/(Loss) before tax (V-VI)	(31.30)	(53.99)	(27.15)	(58.45)	(123.02)	(205.27)
VIII	Tax Expense:						
	Current Tax	-	-	-	-	-	-
	Deferred Tax	(1.04)	-	-	(1.04)	-	(7.11)
IX	Profit/ (Loss) for the period from Continuing operations (VII-VIII)	(30.26)	(53.99)	(27.15)	(57.41)	(123.02)	(198.16)
X	Profit/ (Loss) from discontinuing operations	-	-	-	-	-	-
XI	Tax Expense of discontinuing operations	-	-	-	-	-	-
XII	Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)	-	-	-	-	-	-
XIII	Profit/ (Loss) for the period (IX+XII)	(30.26)	(53.99)	(27.15)	(57.41)	(123.02)	(198.16)
XIV	Other Comprehensive Income						
	A) (i) Items that will not be reclassified to profit or loss						
	(ii) Income Tax related to items that will not be reclassified to profit or loss						
	B) (i) Items that will be reclassified to profit or loss						
	(ii) Income Tax relating to items that will be reclassified to profit or loss	1.42	-	-	1.42	-	1.85
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)	(28.84)	(53.99)	(27.15)	(55.99)	(123.02)	(196.31)
XVI	Comprehensive Income attributable to Non Controlling Interest	(0.29)	-	-	(0.29)	-	(4.45)
XVII	Comprehensive Income attributable to Owners of the company	(28.55)	(53.99)	(27.15)	(55.70)	(123.02)	(191.86)
XVIII	Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each)						
	1) Basic	(0.19)	(0.36)	(0.19)	(0.04)	(0.83)	(1.31)
	2) Diluted	(0.19)	(0.36)	(0.19)	(0.04)	(0.83)	(1.31)
XIX	Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each)						
	1) Basic	-	-	-	-	-	-
	2) Diluted	-	-	-	-	-	-
XX	Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/- each)						
	1) Basic	(0.19)	(0.36)	(0.19)	(0.38)	(0.83)	(1.31)
	2) Diluted	(0.19)	(0.36)	(0.19)	(0.38)	(0.83)	(1.31)
XXI	Paid Up Equity Share Capital (Face Value of INR 10/- per share)	1,480.87	1480.87	1,480.87	1,480.87	1480.87	1480.87

Notes:

- The above unaudited consolidated financial results for the quarter and half year ended 30 September 2020 have been subject to a limited review by the statutory auditors, and reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on Friday 13 November 2020.
- The unaudited consolidated financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under section 133 of Companies Act, 2013 and other accounting principles generally accepted in India and in terms Regulation 33 of SEBI (LODR) Regulations, 2015.
- The format for the consolidated unaudited quarterly and half year ended results as prescribed in SEBI Circular CRI/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply with the requirements of SEBI Circular CRI/CFD/FAC/62/2016 dated July 5, 2016 and exemption as given under clause 2.6.2(i) has been availed.
- The EPS for quarters has not been annualized.
- The company continues to consider the impact of COVID-19 pandemic in assessing the improvement of business and recoverability of receivables. For this purpose, the company considered internal and external sources of information up to the date of approval of these financial results. The Company based on its judgements, estimates and assumptions expects to recover the carrying amount of receivables and other assets. The impact of the global health pandemic may be different from that estimated as at the date of approval of financials results and the Company will continue to closely monitor any material changes to future economic conditions. Entity operated its hospital in the month of June'2020 only for seven days after relaxation of lockdown rules but later the same was shut down and not started till date. Hence there is no revenue in second quarter i.e. July 2020 - September 2020.
- The Company has only one reportable segment i.e., Health Care Sector. Hence, the separate disclosure on Segment information is not required.
- The unaudited financial results for the quarter and half year ended 30 September, 2020 are also available on the website of the Company www.drhsl.com
- The Previous quarters/ year's figures have been regrouped/rearranged wherever necessary, for the purpose of comparison.

Place : Hyderabad
Date : 13/11/2020

For DR HABEEBULLAH LIFE SCIENCES LIMITED

K. Krishnam Raju
Executive Chairman (DIN 00874650)



DR Habeebullah Life Sciences Limited
Consolidated Statement of Assets and Liabilities

Particulars	(Amount in Lakhs.)	
	Half Year Ended 9/30/2020	Year Ended 3/31/2020
ASSETS		
1 Non Current Assets		
a Property, Plant and Equipment	6.95	13.19
b Capital Work In Progress	-	-
c Investment Property	-	-
d Goodwill	-	-
e Other Intangible Assets	-	-
f Intangible Assets under development	-	-
g Biological assets other than bearer plants	1,923.06	1,899.26
h Financial Assets:	-	-
i Investments	-	-
ii Trade Receivables	0.75	0.75
iii Loans	-	-
iv Others	-	-
v Loans	204.28	204.28
vi Others	-	-
i Deferred Tax Assets (net)	-	-
j Other Non Current Assets	47.14	46.10
Total Non Current Assets	2,182.18	2,163.57
2 Current Assets		
a Inventories	12.92	13.11
b Financial Assets:	-	-
i Investments	-	-
ii Trade Receivables	-	-
iii Cash and Cash Equivalents	214.26	217.51
iv Bank balances other than above	1.41	2.94
v Loans	-	-
vi Other financial assets	94.00	94.00
c Current Tax Assets (net)	30.75	24.10
d Other Current Assets	-	-
Total Current Assets	306.21	305.97
	659.55	657.65
Total Assets	2,841.73	2,821.22
EQUITY AND LIABILITIES		
1 Equity		
a Equity Share Capital	1,480.87	1,480.87
b Other Equity:	-	-
i Share Warrants	-	-
ii Reserves and Surplus	(358.26)	(302.56)
iii Non-Controlling Interests	400.26	400.55
Total Equity	1,522.87	1,578.86
2 Liabilities		
Non Current Liabilities		
a Financial Liabilities:	-	-
i Borrowings	-	-
ii Trade Payables	-	-
iii Other Financial Liabilities	-	-
b Provisions	-	-
c Deferred Tax Liabilities (net)	14.48	14.50
d Other Non Current Liabilities	-	-
Total Non Current Liabilities	14.48	14.50
Current Liabilities		
a Financial Liabilities:	-	-
i Borrowings	895.71	858.40
ii Trade Payables	34.93	30.50
iii Other Financial Liabilities	-	-
b Other Current Liabilities	370.91	336.53
c Provisions	2.83	2.43
d Current Tax Liabilities (net)	-	-
Total Current Liabilities	1,304.38	1,227.86
Total Equity and Liabilities	2,841.73	2,821.22

For DR HABEEBULLAH LIFE SCIENCES LIMITED

Place: Hyderabad
Date: 13/11/2020


 K. Krishnam Raju
 Executive Chairman
 (DIN 00874650)



DR HABEEBULLAH LIFE SCIENCES LIMITED
CONSOLIDATED STATEMENT OF CASH FLOWS

(Amount in Lakhs.)

PARTICULARS	Half Year ended September 30, 2020	Half Year ended September 30, 2019
A. CASH FLOW FROM OPERATING ACTIVITIES :		
Net profit before tax	(57.03)	(123.02)
Adjustment for:		
Depreciation and Amortisation	0.66	0.63
Interest Expenses	-	-
Interest Earned	-	(5.64)
Cash Flows from Operations before changes in assets and liabilities	(56.37)	(128.03)
Movements in Working Capital::		
(Increase)/ Decrease in trade receivables	3.26	0.53
(Increase) / Decrease in Short term Loans and Advances	-	-
(Increase)/Decrease in other financial assets Assets	(6.65)	-
(Increase)/Decrease in other Current Assets	(0.24)	(114.75)
(Increase) / Decrease in Inventories	0.19	0.11
Increase / (Decrease) in Trade Payables	4.43	145.53
Increase/(Decrease) in Other current liabilities	34.38	(7.01)
Increase/(Decrease) in Current Provisions	0.40	(0.76)
Change in Working Capital	35.78	23.65
Changes in non current assets and liabilities		
Decrease/(Increase) in loans & advances	-	(1.73)
(Decrease)/Increase in Long Term Provisions	(0.01)	0.76
Changes in non current assets and liabilities	(0.01)	(0.97)
Cash Generated From Operations	(20.61)	(105.35)
Less: Taxes paid	-	-
Net Cash from operating activities(A)	(20.61)	(105.35)
B. CASH FLOW FROM INVESTING ACTIVITIES		
(Increase) / Decrease in Fixed assets and Capital Work In progress	(18.23)	(56.78)
Bank Balances not considered as Cash and Cash equivalents	-	-
Investment in equity Shares	-	-
Interest earned	-	5.64
Net cash used in Investing activities (B)	(18.23)	(51.14)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Increase / (Decrease) in Share Capital	-	150.00
Increase / (Decrease) in Borrowings	37.31	8.10
Interest paid	-	-
Net cash Flow from Financing Activities (C)	37.31	158.10
Net Increase/(Decrease) in cash & cash equivalents [A+B+C]	(1.53)	1.61
CASH & CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	2.94	1.50
CASH & CASH EQUIVALENTS AT THE END OF THE YEAR	1.41	3.11

For and on behalf of the Board
for DR HABEEBULLAH LIFE SCIENCES LIMITED



(K. Krishnam Raju)
Whole-time Director & Chairman
DIN: 00874650



Place: Hyderabad
Date: 13/11/2020

Independent Auditor's Review Report on unaudited quarterly and year to date financial results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To

The Board of Directors

Dr Habeebullah Life Sciences Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Dr Habeebullah Life Sciences Limited** ('the Company') for the quarter ended September, 2020 and the year to-date results for the period April 01, 2020 to September 30,2020 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('the Regulation').
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether financial results are free of material misstatements. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. We draw attention to Note. 5 to the financial results which states that the management has made an assessment of the impact of COVID-19 on the Company's operations, financial performance and position as at and for the period ended September 30, 2020.

MSKA

& Associates

Chartered Accountants

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone financial results prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

For MSKA & Associates

Chartered Accountants

ICAI Firm Registration No.105047W

Digitally signed
by
ananthkrishnan
govindan
Date: 2020.11.13
16:55:15 +05'30'



Ananthkrishnan Govindan

Partner

Membership No: 205226

UDIN: 20205226AAAAJB1064

Place: Hyderabad

Date: November 13,2020

Independent Auditor’s Review Report on Consolidated Unaudited Quarterly and year to date financial results of the Dr Habeebullah Life Sciences Limited and its subsidiary pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To

The Board of Directors

Dr Habeebullah Life Sciences Limited

1. We have reviewed the accompanying statement of consolidated unaudited financial results of **Dr Habeebullah Life Sciences Limited** (‘the Holding Company’), its subsidiary, (the Holding Company and its subsidiary together referred to as the ‘Group’) for the quarter ended September 30, 2020 and the year to-date results for the period from April 01, 2020 to September 30, 2020 (‘the Statement’), being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (‘the Regulation’).
2. This Statement, which is the responsibility of the Holding Company’s Management and approved by the Holding Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 ‘Interim Financial Reporting’ (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entity:

Sr. No	Name of the Company	Relationship with the Holding Company
1	Krisani Bio Sciences Private Limited	Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has

come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We draw attention to Note. 5 to the financial results which states that the management has made an assessment of the impact of COVID-19 on the Company's operations, financial performance and position as at and for the period ended September 30, 2020.
7. The consolidated unaudited financial results include the interim financial information of subsidiary (mentioned in paragraph 4 above) which have not been reviewed or audited by their auditors, whose financial information reflect Group's share of total assets of Rs. 1,657 lakhs (before consolidation adjustments) as at September 30, 2020 and Group's share of total revenue is Nil (before consolidation adjustments) and Group's share of total net loss after tax of Rs. 0.60 lakhs (before consolidation adjustments) for the quarter ended September 30,2020 and for the period from April 01, 2020 to September 30, 2020, respectively, and Group's share of cash flows (net) of Rs. 0.62 lakhs (before consolidation adjustments) for the period from April 01,2020 to September 30,2020 as considered in the consolidated unaudited financial results. The consolidated unaudited financial results also include the Group's share of net loss after tax of Rs. 0.31 lakhs for the half year ended September 30, 2020. According to information and explanation given to us by the management, this interim financial information is not material to the Group.

Our conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the management.

For MSKA & Associates

Chartered Accountants

ICAI Firm Registration No.105047W

ananthkrishnan govindan
Digitally signed by
ananthkrishnan govindan
Date: 2020.11.13 16:55:58
+05'30'



Ananthkrishnan G

Partner

Membership No: 205226

UDIN: 20205226AAAAJC5632

Place: Hyderabad

Date: November 13,2020